[1]段明明,歐陽君,劉賢升.雷珠單抗與康柏西普治療視網膜分支靜脈阻塞繼發黃斑水腫的短期療效比較[J].醫學信息,2020,(04):118-120.[doi:10.3969/j.issn.1006-1959.2020.04.036]
 DUAN Ming-ming,OUYANG Jun,LIU Xian-sheng.Comparison of Short-term Efficacy of Lucentis and Conbercept in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion[J].Medical Information,2020,(04):118-120.[doi:10.3969/j.issn.1006-1959.2020.04.036]
點擊復制

雷珠單抗與康柏西普治療視網膜分支靜脈阻塞繼發黃斑水腫的短期療效比較()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
118-120
欄目:
臨床研究
出版日期:
2020-02-15

文章信息/Info

Title:
Comparison of Short-term Efficacy of Lucentis and Conbercept in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
文章編號:
1006-1959(2020)04-0118-03
作者:
段明明歐陽君劉賢升
(九江市第一人民醫院眼科,江西 九江 332000)
Author(s):
DUAN Ming-mingOUYANG JunLIU Xian-sheng
(Department of Ophthalmology,Jiujiang First People’s Hospital,Jiujiang 332000,Jiangxi,China)
關鍵詞:
視網膜分支靜脈阻塞黃斑水腫雷珠單抗康柏西普
Keywords:
Branch retinal vein occlusionMacular edemaLucentisConbercept
分類號:
R774.1
DOI:
10.3969/j.issn.1006-1959.2020.04.036
文獻標志碼:
A
摘要:
目的 比較雷珠單抗與康柏西普治療視網膜分支靜脈阻塞繼發黃斑水腫的短期療效。方法 選擇2017年1月~2018年3月我院收治非缺血性視網膜分支靜脈阻塞繼發黃斑水腫患者46例(46眼),按隨機數字表法分為A組和B組,每組23例。A組給予雷珠單抗注射,B組給予康柏西普組注射,比較兩組術前、術后1、3個月最佳矯正視力(BCVA)、黃斑中心凹視網膜厚度(CMT)及并發癥發生情況。結果 術后1、3個月,兩組BCVA、CMT均高于術前,差異有統計學意義(P<0.05);兩組BCVA、CMT比較,差異無統計學意義(P>0.05)。兩組并發癥發生率比較,差異無統計學意義(P>0.05)。結論 玻璃體腔注射雷珠單抗或康柏西普治療視網膜分支靜脈阻塞繼發黃斑水腫患者可有效提高BCVA、減少CMT,無明顯全身或眼部重大不良反應,其療效相當。
Abstract:
Objective To compare the short-term efficacy of Lucentis and Conbercept in the treatment of macular edema secondary to retinal vein occlusion.Methods From January 2017 to March 2018, 46 patients (46 eyes) with non-ischemic branch retinal vein occlusion secondary macular edema were treated in our hospital, and according to the random number table method,they were divided into group A and group B, 23 examples in each group. Group A was injected with Lucentis, and group B was injected with Conbercept and the best corrected visual acuity (BCVA), retinal thickness in macular fovea (CMT) and complications between the two groups 1 and 3 months after operation.Results At 1 and 3 months after operation, the BCVA and CMT in the two groups were higher than before surgery,the difference was statistically significant (P<0.05). There was no significant difference in BCVA and CMT between the two groups(P>0.05). There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion Intravitreal injection of Lucentis or Conbercept in patients with secondary macular edema due to branch retinal vein occlusion can effectively increase BCVA and reduce CMT, without significant systemic or ocular major adverse effects, and its efficacy is comparable.

參考文獻/References:

[1]Parodi MB,Bandello F.Branch retinal vein occlusion:classifica-tion and treatment[J].Ophthalmologica,2009,223(5):298-305. [2]Oellers P,Grewal DS,Fekrat S.Role of aflibercept for macular edema following branch retinal vein occlusion:comparison of clinical trials[J].Clin Ophthalmology,2016(10):411-418. [3]Zhang S,An N,Ha W,et al.Factors correlated with the resolution ofmacular oedema after one dose injection of intravitreal triamcinoloneacetonide treatment in branch retinal vein occlusion[J].Journal of International Medical Research,2016,44(3):685-697. [4]褚夢琪.視網膜靜脈阻塞繼發黃斑水腫的最新治療進展[J].中華實驗眼科雜志,2018,36(1):65-69. [5]邢凱,亢澤峰.玻璃體腔內注射康柏西普治療視網膜分支靜脈阻塞繼發黃斑水腫的療效分析[J].山東大學耳鼻喉眼學報,2016(1):80-82. [6]Wu Z,Zhou P,Li X,et al.Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling[J].PLoS One,2013,8(3):e57642. [7]王琛,李東豪,聞毅頤.玻璃體內注射康柏西普聯合周邊視網膜選擇性光凝治療視網膜靜脈阻塞繼發黃斑水腫的療效及安全性[J].眼科新進展,2016,36(5):471-473. [8]楊林紅,皇甫昌濤,朱琳,等.眼內注射康柏西普治療視網膜分支靜脈阻塞繼發黃斑水腫的臨床觀察[J].昆明醫科大學學報,2015,36(11):147-149. [9]連海燕,宋艷萍,丁琴,等.康柏西普與雷珠單抗玻璃體腔注射治療視網膜中央靜脈阻塞黃斑水腫短期療效對比觀察[J].中華眼底病雜志,2016,32(4):367-371.

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 在线配资开户全信久联配资 炒股投资 秒速时时彩技巧公式 深圳风采开奖号码查询 河南11选5走势图表 好彩1对应生肖 期货配资公司名录 股票配资网站排名 江苏快3app怎么下载 河北快三的结果